<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="176442">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00798590</url>
  </required_header>
  <id_info>
    <org_study_id>NA_00022551</org_study_id>
    <nct_id>NCT00798590</nct_id>
  </id_info>
  <brief_title>The Efficacy of GLP - 1(7-36) Amide for Glycemic Control in Critically Ill Patients</brief_title>
  <official_title>The Efficacy of GLP - 1 (7-36) Amide for Glycemic Control in Critically Ill Surgical Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Society of Critical Care Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this present proposal is to examine the efficacy of GLP-1 administered to
      control blood glucose in critically ill patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All patients whom on admission to the ICU (surgical, burn, &amp; cardiac) who are expected to
      receive intensive insulin therapy for at least 72 hours are eligible to be enrolled. Once
      enrolled, the patients will be randomized to one of two groups: the experimental
      (intravenous GLP-1 infusion for 72 hours) or control groups (intravenous 0.9% NaCl infusion
      for 72 hours) in a double masked fashion. While enrolled, all patients will receive
      standard-of-care insulin therapy. Both groups will be maintained on the standard ICU
      specific protocol for glucose control.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Enrolling by invitation</last_known_status>
  <start_date>December 2008</start_date>
  <completion_date type="Anticipated">June 2011</completion_date>
  <primary_completion_date type="Anticipated">June 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To compare the composite overall amount of insulin used with GLP-1 vs. placebo to reach and maintain the ICU-specific target glucose range.</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compare the # of hypoglycemic events between GLP-1/placebo treatment;Amount of meds in the control of homeostasis;Death in the ICU/in-hospital;Time of ICU stay/hospitalization;ICU infection rate;Time of ventilator support to time of extubation.</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Critically Ill</condition>
  <condition>Hypoglycemia</condition>
  <arm_group>
    <arm_group_label>GLP-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glucagon-Like Peptide-1</intervention_name>
    <description>5ng/kg-1/min-1 GLP-1 infused in 3 ml continuously over 72 hours.</description>
    <arm_group_label>GLP-1</arm_group_label>
    <other_name>GLP-1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>5ng/kg-1/min-1 placebo infused in 3 ml continuously over 72 hours.</description>
    <arm_group_label>Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women age &gt; 21 to 75 years of age.

          -  All subjects who meet ICU specific criteria for inclusion in their glucose protocol
             and placed on insulin infusion protocol as standard of care.

          -  Able to obtain patient or proxy consent.

        Exclusion Criteria:

          -  Current diagnosis of malignancy.

          -  Type 1 diabetes.

          -  Inability to obtain informed consent.

          -  On any Phase 1 trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dariush Elahi, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins Bayview Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2010</verification_date>
  <lastchanged_date>March 25, 2010</lastchanged_date>
  <firstreceived_date>November 25, 2008</firstreceived_date>
  <responsible_party>
    <name_title>Dariush Elahi</name_title>
    <organization>Johns Hopkins University School of Medicine</organization>
  </responsible_party>
  <keyword>Intensive insulin therapy (IIT)</keyword>
  <keyword>Insulin infusion</keyword>
  <keyword>Tight glycemic control</keyword>
  <keyword>Intensive Care Units</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Critical Illness</mesh_term>
    <mesh_term>Hypoglycemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glucagon</mesh_term>
    <mesh_term>Glucagon-Like Peptide 1</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
